Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | OPA1 | O60313 | 1/20 | 0.40 |
| ▸ | EIF5B | O60841 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2874439 | 0.99 | HTR2A (0.56) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL2348471 | 0.87 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL2879591 | 0.86 | MTNR1A (0.53) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL12450012 | 0.86 | MTNR1A (0.57) | HTR2AHTR2CMTNR1AMTNR1BGAA | |
| SCHEMBL14012424 | 0.84 | MTNR1A (0.51) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL2342187 | 0.83 | HTR2A (0.48) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL1395799 | 0.83 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL2260099 | 0.82 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL27977245 | 0.82 | HTR2A (0.51) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL2023775 | 0.82 | HTR2A (0.51) | HTR2AHTR2CMTNR1AMTNR1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | PYCR1, DHPS, TYMP | HTR2A 3957/4885HTR2C 2099/4885MTNR1A 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.